215 related articles for article (PubMed ID: 33296082)
1. Endogenous fibrinolysis-Relevance to clinical thrombosis risk assessment.
Kanji R; Kubica J; Navarese EP; Gorog DA
Eur J Clin Invest; 2021 Apr; 51(4):e13471. PubMed ID: 33296082
[TBL] [Abstract][Full Text] [Related]
2. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction.
Saraf S; Christopoulos C; Salha IB; Stott DJ; Gorog DA
J Am Coll Cardiol; 2010 May; 55(19):2107-15. PubMed ID: 20447533
[TBL] [Abstract][Full Text] [Related]
3. Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study.
Farag M; Spinthakis N; Gue YX; Srinivasan M; Sullivan K; Wellsted D; Gorog DA
Eur Heart J; 2019 Jan; 40(3):295-305. PubMed ID: 30380032
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome.
Gue YX; Kanji R; Wellsted DM; Srinivasan M; Wyatt S; Gorog DA
J Thromb Thrombolysis; 2020 Feb; 49(2):192-198. PubMed ID: 31872349
[TBL] [Abstract][Full Text] [Related]
5. Arterial and venous thrombosis by high platelet count and high hematocrit: 108 521 individuals from the Copenhagen General Population Study.
Warny M; Helby J; Birgens HS; Bojesen SE; Nordestgaard BG
J Thromb Haemost; 2019 Nov; 17(11):1898-1911. PubMed ID: 31309714
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection.
Wright FL; Vogler TO; Moore EE; Moore HB; Wohlauer MV; Urban S; Nydam TL; Moore PK; McIntyre RC
J Am Coll Surg; 2020 Aug; 231(2):193-203.e1. PubMed ID: 32422349
[TBL] [Abstract][Full Text] [Related]
7. Endogenous Fibrinolysis: An Important Mediator of Thrombus Formation and Cardiovascular Risk.
Okafor ON; Gorog DA
J Am Coll Cardiol; 2015 Apr; 65(16):1683-1699. PubMed ID: 25908074
[TBL] [Abstract][Full Text] [Related]
8. Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis.
Lisman T
Semin Thromb Hemost; 2017 Mar; 43(2):178-184. PubMed ID: 27472427
[TBL] [Abstract][Full Text] [Related]
9. Severe SARS-CoV-2 Infection Inhibits Fibrinolysis Leading to Changes in Viscoelastic Properties of Blood Clot: A Descriptive Study of Fibrinolysis in COVID-19.
Hammer S; Häberle H; Schlensak C; Bitzer M; Malek NP; Handgretinger R; Lang P; Hörber S; Peter A; Martus P; Mirakaj V; Gawaz M; Geisler T; Althaus K; Rosenberger P; Bakchoul T
Thromb Haemost; 2021 Nov; 121(11):1417-1426. PubMed ID: 33634444
[TBL] [Abstract][Full Text] [Related]
10. Impaired endogenous fibrinolysis at high shear using a point-of-care test in STEMI is associated with alterations in clot architecture.
Spinthakis N; Gue Y; Farag M; Ren G; Srinivasan M; Baydoun A; Gorog DA
J Thromb Thrombolysis; 2019 Apr; 47(3):392-395. PubMed ID: 30739303
[TBL] [Abstract][Full Text] [Related]
11. Difference in fibrinolytic capacity in young patients with venous thrombosis or ischaemic stroke.
Skov J; Sidelmann JJ; Bladbjerg EM; Jespersen J; Gram J
Blood Coagul Fibrinolysis; 2014 Jan; 25(1):61-6. PubMed ID: 23963096
[TBL] [Abstract][Full Text] [Related]
12. Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.
Memtsas VP; Arachchillage DRJ; Gorog DA
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540604
[TBL] [Abstract][Full Text] [Related]
13. Impaired endogenous fibrinolysis status: a potential prognostic predictor in ischemic stroke.
Chen Y; Gue Y; McDowell G; Gorog DA; Lip GYH
Minerva Med; 2024 Jun; 115(3):364-379. PubMed ID: 38727704
[TBL] [Abstract][Full Text] [Related]
14. Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis.
Lau YC; Xiong Q; Ranjit P; Lip GY; Blann AD
J Thromb Thrombolysis; 2016 Aug; 42(2):233-44. PubMed ID: 26942726
[TBL] [Abstract][Full Text] [Related]
15. Impaired Spontaneous/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor?: JACC Review Topic of the Week.
Gorog DA; Lip GYH
J Am Coll Cardiol; 2019 Sep; 74(10):1366-1375. PubMed ID: 31488274
[TBL] [Abstract][Full Text] [Related]
16. Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to lytic therapy.
Sambola A; García Del Blanco B; Ruiz-Meana M; Francisco J; Barrabés JA; Figueras J; Bañeras J; Otaegui I; Rojas A; Vilardosa Ú; Montaner J; García-Dorado D
Thromb Haemost; 2016 Jun; 115(6):1129-37. PubMed ID: 26962963
[TBL] [Abstract][Full Text] [Related]
17. Fibrin clot formation and fibrinolysis in patients with a history of coronary stent thrombosis.
Godschalk TC; Konings J; Govers-Riemslag JW; Ten Berg JM; Hackeng CM; Ten Cate H
Thromb Res; 2016 Jul; 143():58-62. PubMed ID: 27191854
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis in Venous Thromboembolism.
Undas A
Semin Thromb Hemost; 2021 Jul; 47(5):480-489. PubMed ID: 33878786
[TBL] [Abstract][Full Text] [Related]
19. Thrombosis and fibrinolysis in acute myocardial infarction.
Eisenberg PR
Alcohol Clin Exp Res; 1994 Feb; 18(1):97-104. PubMed ID: 8198233
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolysis Shutdown and Thrombosis in a COVID-19 ICU.
Creel-Bulos C; Auld SC; Caridi-Scheible M; Barker NA; Friend S; Gaddh M; Kempton CL; Maier CL; Nahab F; Sniecinski R
Shock; 2021 Mar; 55(3):316-320. PubMed ID: 32769822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
